COMP <GO>
CGON vs ADPT // 10Y YIELD & FRED MACRO BETA
CG Oncology Inc. (NASDAQ) VS. Adaptive Biotechnologies Corporation (NASDAQ) • 15-METRIC TALLY: CGON 6
— ADPT 5
▲ 10Y YIELD & FRED MACRO BETA LEADER: CGON
LAST: $63.47 (-0.77%) • MKT CAP: $5.63B
macro-sensitivity
1.07
LAST: $28.17 (-0.70%) • MKT CAP: $4.50B
macro-sensitivity
1.01
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. ADPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGON | ADPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.80% | -12.50% | -8.30 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.35% | -1.09% | -1.26 | ADPT | /fcf-yield <GO> |
| Operating Margin | -12.10% | -20.60% | +8.50 | CGON | /operating-margins <GO> |
| Net Profit Margin | -10.20% | -21.50% | +11.30 | CGON | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | 54.80% | -46.00 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.32 | +19.68 | CGON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 57.6 | -12.30 | ADPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.07 | 1.01 | +0.06 | CGON | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 26.0x | -6.00 | CGON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.63B | $4.50B | $1.13B | CGON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGON REV | ADPT REV | CGON GROSS % | ADPT GROSS % | CGON FCF | ADPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $277.0M | — | 74.2% | -$132.5M | -$48.9M |
| FY 2024 | $0 | $179.0M | — | 59.7% | -$78.9M | -$98.9M |
| FY 2023 | $0 | $170.3M | — | — | -$45.7M | -$164.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
ADPT // BETA 1.01